Recent advances in understanding the role of serotonin in gastrointestinal motility in functional bowel disorders: Alterations in 5-HT signalling and metabolism in human disease

Neurogastroenterology and Motility

Volumn 19, Issue SUPPL.2, 2007, Pages 25-31

  Spiller, R ^a  

^a Wolfson Digestive Diseases Centre   (United Kingdom)

Author keywords

Irritable bowel syndrome; Motility; Secretion; Serotonin

Indexed keywords

1 METHYL 3 INDOLECARBOXYLIC ACID [1 [2 (METHYLSULFONYLAMINO)ETHYL] 4 PIPERIDINYLMETHYL] ESTER; 4,7 DIHYDRO 7 OXO N (3 QUINUCLIDINYL)THIENO[3,2 B]PYRIDINE 6 CARBOXAMIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CISPLATIN; GRANISETRON; KETANSERIN; ONDANSETRON; PENTAGASTRIN; PROPRANOLOL; PRUCALOPRIDE; SEROTONIN; SEROTONIN 2 ANTAGONIST; SEROTONIN 2 RECEPTOR; SEROTONIN 3 AGONIST; SEROTONIN 3 ANTAGONIST; SEROTONIN 4 AGONIST; SEROTONIN 4 ANTAGONIST; SEROTONIN TRANSPORTER; TEGASEROD; TRINITROBENZENESULFONIC ACID; UNCLASSIFIED DRUG;

AUTONOMIC NERVOUS SYSTEM; CAMPYLOBACTER JEJUNI; CARCINOID SYNDROME; CELIAC DISEASE; CHEMOTHERAPY INDUCED EMESIS; CHROMAFFIN GRANULE; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DRUG BIOAVAILABILITY; ENTERITIS; ENTEROCHROMAFFIN CELL; GASTROINTESTINAL DISEASE; GASTROINTESTINAL MOTILITY; GASTROINTESTINAL MOTILITY DISORDER; GASTROINTESTINAL MUCOSA; GASTROINTESTINAL SECRETION; GASTROINTESTINAL TRACT FUNCTION; HUMAN; HYMENOLEPIS DIMINUTA; INTESTINE INFECTION; INTESTINE INNERVATION; IRRITABLE COLON; MOTONEURON; MYENTERIC PLEXUS; NAUSEA; NONHUMAN; PRIORITY JOURNAL; REVIEW; SEROTONIN RELEASE; SEROTONINERGIC NERVE CELL; SEROTONINERGIC SYSTEM; TRICHINELLA SPIRALIS; VOMITING;

ANTINEOPLASTIC AGENTS; CAMPYLOBACTER INFECTIONS; CELIAC DISEASE; CISPLATIN; COLONIC DISEASES, FUNCTIONAL; GASTROINTESTINAL MOTILITY; HUMANS; INTESTINAL MUCOSA; IRRITABLE BOWEL SYNDROME; MALIGNANT CARCINOID SYNDROME; SEROTONIN; SEROTONIN AGONISTS; SIGNAL TRANSDUCTION;

EID: 34447136135     PISSN: 13501925     EISSN: 13652982     Source Type: Journal    
DOI: 10.1111/j.1365-2982.2007.00965.x     Document Type: Review

References (53)

1. Cubeddu LX, Hoffmann IS, Fuenmayor NT, Malave JJ. Changes in serotonin metabolism in cancer patients: its relationship to nausea and vomiting induced by chemotherapeutic drugs. Br J Cancer 1992 66 : 198 203.
2. der Ohe MR, Camilleri M, Kvols LK. A 5HT3 antagonist corrects the postprandial colonic hypertonic response in carcinoid diarrhea. Gastroenterology 1994 106 : 1184 9.
3. Gore S, Gilmore IT, Haigh CG, Brownless SM, Stockdale H, Morris AI. Colonic transit in man is slowed by ondansetron (GR38032F), a selective 5-hydroxytryptamine receptor (type 3) antagonist. Aliment Pharmacol Ther 1990 4 : 139 44.
4. Linden DR, Chen JX, Gershon MD, Sharkey KA, Mawe GM. Serotonin availability is increased in mucosa of guinea pigs with TNBS-induced colitis. Am J Physiol Gastrointest Liver Physiol 2003 285 : G207 16.
5. Christofi FL, Kim M, Wunderlich JE et al. Endogenous adenosine differentially modulates 5-hydroxytryptamine release from a human enterochromaffin cell model. Gastroenterology 2004 127 : 188 202.
6. Martin DC, Magnant AD, Kellum JM Jr. Luminal hypertonic solutions stimulate concentration-dependent duodenal serotonin release. Surgery 1989 106 : 325 31.
7. Kellum JM, Jaffe BM. Release of immunoreactive serotonin following acid perfusion of the duodenum. Ann Surg 1976 184 : 633 6.
8. Ferrara A, Zinner MJ, Jaffe BM. Intraluminal release of serotonin, substance P, and gastrin in the canine small intestine. Dig Dis Sci 1987 32 : 289 94.
9. Krishnaswamy S, Duan SX, Von Moltke LL et al. Serotonin (5-hydroxytryptamine) glucuronidation in vitro: assay development, human liver microsome activities and species differences. Xenobiotica 2003 33 : 169 80.
10. Hansen MB, Skadhauge E. Signal transduction pathways for serotonin as an intestinal secretagogue. Comp Biochem Physiol A Physiol 1997 118 : 283 90.
11. Kirchgessner AL, Tamir H, Gershon MD. Identification and stimulation by serotonin of intrinsic sensory neurons of the submucosal plexus of the guinea pig gut: activity-induced expression of Fos immunoreactivity. J Neurosci 1992 12 : 235 48.
12. McLean PG, Coupar IM. Investigation into the effect of 5-hydroxytryptamine on fluid transport in the rat small intestine. Gen Pharmacol 1998 30 : 227 31.
13. Budhoo MR, Kellum JM. Evidence for a 5-HT4 receptor pathway mediating chloride secretion in the rat distal colon. J Surg Res 1994 57 : 44 8.
14. Kellum JM, Budhoo MR, Siriwardena AK, Smith EP, Jebraili SA. Serotonin induces Cl- secretion in human jejunal mucosa in vitro via a nonneural pathway at a 5-HT4 receptor. Am J Physiol 1994 267 : G357 63.
15. Foxx-Orenstein AE, Kuemmerle JF, Grider JR. Distinct 5-HT receptors mediate the peristaltic reflex induced by mucosal stimuli in human and guinea pig intestine. Gastroenterology 1996 111 : 1281 90.
16. Nakajima M, Shiihara Y, Shiba Y et al. Effect of 5-hydroxytryptamine on gastrointestinal motility in conscious guinea-pigs. Neurogastroenterol Motil 1997 9 : 205 14.
17. Lordal M, Hellstrom PM. Serotonin stimulates migrating myoelectric complex via 5-HT3-receptors dependent on cholinergic pathways in rat small intestine. Neurogastroenterol Motil 1999 11 : 1 10.
18. Lordal M, Wallen H, Hjemdahl P, Beck O, Hellstrom PM. Concentration-dependent stimulation of intestinal phase III of migrating motor complex by circulating serotonin in humans. Clin Sci (Colch) 1998 94 : 663 70.
19. Fujita T, Yokota S, Sawada M, Majima M, Ohtani Y, Kumagai Y. Effect of MKC-733, a 5-HT receptor partial agonist, on bowel motility and symptoms in subjects with constipation: an exploratory study. J Clin Pharm Ther 2005 30 : 611 22.
20. Ahlman H, Dahlstrom A, Gronstad K et al. The pentagastrin test in the diagnosis of the carcinoid syndrome. Blockade of gastrointestinal symptoms by ketanserin. Ann Surg 1985 201 : 81 6.
21. Gronstad KO, Ahlund L, Dahlstrom A, Haggendal J, Ahlman H. A possible mechanism for the release of serotonin from the gut caused by pentagastrin. J Surg Res 1988 44 : 473 8.
22. Ahlman H, Ahlund L, Dahlstrom A, Martner J, Stenqvist O, Tylen U. SMS 201-995 and provocation tests in preparation of patients with carcinoids for surgery or hepatic arterial embolization. Anesth Analg 1988 67 : 1142 8.
23. Saslow SB, O'Brien MD, Camilleri M et al. Octreotide inhibition of flushing and colonic motor dysfunction in carcinoid syndrome. Am J Gastroenterol 1997 92 : 2250 6.
24. O'Toole D, Ducreux M, Bommelaer G et al. Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance. CA 2000 88 : 770 6.
25. von der O, Camilleri M, Kvols LK, Thomforde GM. Motor dysfunction of the small bowel and colon in patients with the carcinoid syndrome and diarrhea (erratum appears in N Engl J Med 1993; 329: 1592). N Engl J Med 1993 329 : 1073 8.
26. Castejon AM, Paez X, Hernandez L, Cubeddu LX. Use of intravenous microdialysis to monitor changes in serotonin release and metabolism induced by cisplatin in cancer patients: comparative effects of granisetron and ondansetron. J Pharmacol Exp Ther 1999 291 : 960 6.
27. Hawthorn J, Ostler KJ, Andrews PL. The role of the abdominal visceral innervation and 5-hydroxytryptamine M-receptors in vomiting induced by the cytotoxic drugs cyclophosphamide and cis-platin in the ferret. Q J Exp Physiol 1988 73 : 7 21.
28. Hillsley K, Grundy D. Serotonin and cholecystokinin activate different populations of rat mesenteric vagal afferents. Neurosci Lett 1998 255 : 63 6.
29. Hillsley K, Grundy D. Plasticity in the mesenteric afferent response to cisplatin following vagotomy in the rat. J Auton Nerv Syst 1999 76 : 93 8.
30. Challacombe DN, Dawkins PD, Baker P. Increased tissue concentrations of 5-hydroxytryptamine in the duodenal mucosa of patients with coeliac disease. Gut 1977 18 : 882 6.
31. Sjolund K, Nobin A. Increased levels of plasma 5-hydroxytryptamine in patients with coeliac disease. Scand J Gastroenterol 1985 20 : 304 8.
32. Challacombe DN, Brown GA, Black SC, Storrie MH. Increased excretion of 5-hydroxyindoleacetic acid in urine of children with untreated coeliac disease. Arch Dis Child 1972 47 : 442 5.
33. Coleman NS, Foley S, Dunlop SP et al. Abnormalities of serotonin metabolism and their relation to symptoms in untreated celiac disease. Clin Gastroenterol Hepatol 2006 4 : 874 81.
34. Foley S, Coleman N, Holmes GKT, Bennett A, Spiller RC. Serotonin transporter expression is reduced in celiac disease. Gastroenterology 2006 130 : A740.
35. Deprez P, Sempoux C, Van Beers BE et al. Persistent decreased plasma cholecystokinin levels in celiac patients under gluten-free diet: respective roles of histological changes and nutrient hydrolysis. Regul Pept 2002 110 : 55 63.
36. Rubin DC, Zhang H, Qian P, Lorenz RG, Hutton K, Peters MG. Altered enteroendocrine cell expression in T cell receptor alpha chain knock-out mice. Microsc Res Tech 2000 51 : 112 20.
37. Wheatcroft J, Wakelin D, Smith A, Mahoney CR, Mawe G, Spiller R. Enterochromaffin cell hyperplasia and decreased serotonin transporter in a mouse model of postinfectious bowel dysfunction. Neurogastroenterol Motil 2005 17 : 863 70.
38. Spiller RC, Jenkins D, Thornley JP et al. Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut 2000 47 : 804 11.
39. Dunlop SP, Jenkins D, Neal KR, Spiller RC. Relative importance of enterochromaffin cell hyperplasia, anxiety, and depression in postinfectious IBS. Gastroenterology 2003 125 : 1651 9.
40. O'Hara JR, Ho W, Linden DR, Mawe GM, Sharkey KA. Enteroendocrine cells and 5-HT availability are altered in mucosa of guinea pigs with TNBS ileitis. Am J Physiol Gastrointest Liver Physiol 2004 287 : G998 1007.
41. El Salhy M, Danielsson A, Stenling R, Grimelius L. Colonic endocrine cells in inflammatory bowel disease. J Intern Med 1997 242 : 413 9.
42. Kyosola K, Penttila O, Salaspuro M. Rectal mucosal adrenergic innervation and enterochromaffin cells in ulcerative colitis and irritable colon. Scand J Gastroenterol 1977 12 : 363 7.
43. Bishop AE, Pietroletti R, Taat CW, Brummelkamp WH, Polak JM. Increased populations of endocrine cells in Crohn's ileitis. Virchows Arch A Pathol Anat Histopathol 1987 410 : 391 6.
44. Pietroletti R, Blaauwgeers JL, Taat CW, Simi M, Brummelkamp WH, Becker AE. Intestinal endocrine cells in radiation enteritis. Surg Gynecol Obstet 1989 169 : 127 30.
45. Magro F, Vieira-Coelho MA, Fraga S et al. Impaired synthesis or cellular storage of norepinephrine, dopamine, and 5-hydroxytryptamine in human inflammatory bowel disease. Dig Dis Sci 2002 47 : 216 24.
46. Bearcroft CP, Perrett D, Farthing MJ. Postprandial plasma 5-hydroxytryptamine in diarrhoea predominant irritable bowel syndrome: a pilot study. Gut 1998 42 : 42 6.
47. Cremonini F, Delgado-Aros S, Camilleri M. Efficacy of alosetron in irritable bowel syndrome: a meta-analysis of randomized controlled trials. Neurogastroenterol Motil 2003 15 : 79 86.
48. Houghton LA, Atkinson W, Whitaker RP, Whorwell PJ, Rimmer MJ. Increased platelet depleted plasma 5-hydroxytryptamine concentration following meal ingestion in symptomatic female subjects with diarrhoea predominant irritable bowel syndrome. Gut 2003 52 : 663 70.
49. Dunlop SP, Coleman NS, Blackshaw E et al. Abnormalities of 5-hydroxytryptamine metabolism in irritable bowel syndrome. Clin Gastroenterol Hepatol 2005 3 : 349 57.
50. Atkinson W, Lockhart S, Whorwell PJ, Keevil B, Houghton LA. Altered 5-hydroxytryptamine signaling in patients with constipation- and diarrhea-predominant irritable bowel syndrome. Gastroenterology 2006 130 : 34 43.
51. Miwa J, Echizen H, Matsueda K, Umeda N. Patients with constipation-predominant irritable bowel syndrome (IBS) may have elevated serotonin concentrations in colonic mucosa as compared with diarrhea-predominant patients and subjects with normal bowel habits. Digestion 2001 63 : 188 94.
52. Bouras EP, Camilleri M, Burton DD, Thomforde G, McKinzie S, Zinsmeister AR. Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder. Gastroenterology 2001 120 : 354 60.
53. Prather CM, Camilleri M, Zinsmeister AR, McKinzie S, Thomforde G. Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome. Gastroenterology 2000 118 : 463 8.